<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642717</url>
  </required_header>
  <id_info>
    <org_study_id>1276-0039</org_study_id>
    <nct_id>NCT03642717</nct_id>
  </id_info>
  <brief_title>Regulatory Request NIS in Korea</brief_title>
  <official_title>A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of JARDIANCE DUO® (Empagliflozin/Metformin, 5/500mg, 5/850mg, 5/1000mg, 12.5/500mg, 12.5/850mg, 12.5/1000mg) in Korean Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To monitor the safety profile and effectiveness of JARDIANCE DUO® in Korean patients with
      type 2 diabetes mellitus in a routine clinical practice setting
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 21, 2018</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>at week 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in the glycosylated hemoglobin (HbA1c) from baseline</measure>
    <time_frame>upto 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">635</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Subjects diagnosed with type 2 diabetes mellitus</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JARDIANCE DUO®</intervention_name>
    <description>empagliflozin and metformin</description>
    <arm_group_label>Subjects diagnosed with type 2 diabetes mellitus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is an observational prospective, non-interventional, open-label, multi-centre national
        study. It will provide additional safety information of JARDIANCE DUO®
        (empagliflozin/metformin) in Korean patients with type 2 diabetes mellitus in a routine
        clinical practice setting
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have started at first time on JARDIANCE DUO® in accordance with the
             approved label in Korea

          -  Age ≥19 years at enrolment

          -  Patients who have signed on the data release consent form

        Exclusion Criteria:

          -  Patients with previous exposure to JARDIANCE®, JARDIANCE DUO®

          -  Hypersensitivity to active ingredients empagliflozin and/or metformin or to any of the
             excipients

          -  Moderate (stage 3b) and severe renal failure (CrCl &lt; 45 ml/min or eGFR &lt; 45
             ml/min/1.73 square meter)

          -  Acute conditions with the potential to alter renal function such as: dehydration,
             severe infection, cardiovascular collapse (shock), acute myocardial infarction, sepsis

          -  Type1 diabetes, acute or chronic metabolic acidosis, including diabetic ketoacidosis
             with or without coma, history of a ketoacidosis (type 1 diabetes and diabetic
             ketoacidosis should be treated with insulin).

          -  Congestive heart failure requiring pharmacologic management, in particular those with
             unstable or acute congestive heart failure

          -  Radiologic studies involving the use of intravascular iodinated contrast materials
             (for example, intravenous urogram, intravenous cholangiography, angiography, and
             computed tomography (CT) scans with intravascular contrast materials)

          -  Intravascular administration of iodinated contrast media may lead to acute renal
             failure and has been associated with lactic acidosis in patients receiving metformin.

        Therefore, in patients with eGFR &gt; 60ml/min/1.73m2, JARDIANCE DUO® must be discontinued
        prior to, or at the time of the test and not be reinstituted until 48 hoursafterwards, and
        only after renal function has been re-evaluated and has not deteriorated further. In
        patients with moderate renal impairment (eGFR 45-60 ml/min/1.73m2), JARDIANCE DUO® must be
        discontinued 48 hours before administration of iodinated contrast media and not be
        reinstituted until at least 48 hours afterwards, and only after renal function has been
        re-evaluated and has not deteriorated further.

          -  In patients with severe infections or severe traumatic systemic disorders, JARDIANCE
             DUO® should be temporarily suspended, and should not be restarted until the patient's
             oral intake has resumed and renal function has been evaluated as normal.

          -  JARDIANCE DUO® should be temporarily suspended for any surgical procedure(except minor
             procedures not associated with restricted intake of food and fluids)before 48 hours,
             and not be reinstituted until 48 hours afterwards, after renal function has been
             evaluated as normal.

          -  Patients with malnutrition, starvation, hypostheniam pituitary or adrenal
             insufficiency

          -  Impaired hepatic function (since impaired hepatic function has been associated with
             some cases of lactic acidosis, JARDIANCE DUO® should generally be avoided in patients
             with clinical or laboratory evidence of hepatic disease), pulmonary infarction, severe
             respiratory impairment, any condition associated with hypoxemia, excessive alcohol
             intake, GI disorders such as dehydration, diarrhoea or vomiting

          -  Pregnant women, women who may be pregnant, nursing women

          -  Disease which may cause tissue hypoxia (especially acute disease, or worsening of
             chronic disease) such as: decompensated heart failure, respiratory failure, recent
             myocardial infarction, shock

          -  Current participation in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane(JiEun) Lee, 8227090092</last_name>
    <role>Study Chair</role>
    <affiliation>jane.lee.ext@boehringer-ingelheim.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyewon Medical Foundation Sejong Hospital</name>
      <address>
        <city>Bucheon</city>
        <zip>14754</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>48108</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Myongji Hospital</name>
      <address>
        <city>Goyang</city>
        <zip>10475</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Sanggye Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>01757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>02053</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SoonChunHyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hongik Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07937</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). Requestors can use the following link http://trials.boehringer-ingelheim.com/ to:
find information in order to request access to clinical study data, for listed studies.
request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

